Drug Pricing
Our work in Drug Pricing
-
Who Wins When a Prescription Copay Exceeds the Drug Price? (Not the Patient)
Use an interactive graph to see how frequently a co-payment exceeds the price of commonly prescribed drugs and the average size of the overpayment.
-
Cultivating a Vibrant U.S. Market for Biosimilars: a Conversation with FDA’s Scott Gottlieb
Biosimilars have been a major focus of the FDA’s efforts to increase competition and choice for patients and the U.S. healthcare system.
Categorized in -
Growing Number of Unsubsidized Part D Beneficiaries with Catastrophic Spending Suggests Need for Out-Of-Pocket Cap
More than one million Part D enrollees who were not eligible for cost assistance reached the catastrophic coverage in 2015.
Categorized in -
Productivity Benefits of Medical Care: Evidence from US-Based Randomized Clinical Trials
Drug innovation in the last decade increased productivity by 4.8 million work days, resulting in $221 billion in annual wages.
Categorized in -
Economics of the Pharmaceutical Industry
Darius Lakdawalla reviews the economics literature on the pharmaceutical industry, focusing particularly on its positive and normative implications for the innovation, pricing, and marketing decisions of pharmaceutical firms.
Categorized in -
New Payment Strategy Could Help States Treat More Hepatitis C Patients While Encouraging Innovation
A curative treatment exists for chronic hepatitis C infection, yet many Medicaid beneficiaries do not have access to these drugs. Neeraj Sood and his colleagues have developed a novel pricing strategy to expand access.
Categorized in -
Why Health Price Regulations in California are Misguided
Imposing uniform payment rates is dangerous and misguided, writes Trish and Goldman in the Sacramento Bee.
Categorized in -
USC Recruits Diverse Participants for Landmark $1.5 Billion Precision Medicine Research Initiative
Nationwide big data project seeks to accelerate research and improve health for a diverse population, not just majority groups.
-
Accelerating Alzheimer’s Disease Drug Innovations from the Research Pipeline to Patients
Goldman, Fillit, and Neumann outline policy options that would lead to more innovation.
Categorized in -
Innovation in Heart Failure Treatment: Life Expectancy, Disability, and Health Disparities
Using the Future Elderly Model, researchers evaluated the potential health benefits from innovation in heart failure treatment.
Categorized in